help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on December 14, 2006
Endocrinology, doi:10.1210/en.2006-0923
A more recent version of this article appeared on March 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
148/3/1306    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, C. S.
Right arrow Articles by Cheng, S.-y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, C. S.
Right arrow Articles by Cheng, S.-y.

Submitted on July 10, 2006
Accepted on December 1, 2006

Gelsolin: a novel thyroid hormone receptor {beta} interacting protein that modulates tumor progression in a mouse model of follicular thyroid cancer

Caroline S. Kim, Fumihiko Furuya, Hao Ying, Yasuhito Kato, John A. Hanover, and Sheue-yann Cheng*

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer; Institute and Laboratory of Cellular Biochemistry and Biology, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892-4264

* To whom correspondence should be addressed. E-mail: chengs{at}mail.nih.gov.

Follicular thyroid cancer (FTC) is known to metastasize to distant sites via hematogenous spread; however, the underlying pathways that contribute to metastasis remain unknown. Recent creation of a knockin mutant mouse that expresses a mutant thyroid hormone receptor {beta} (TR{beta}PV/PV mouse) that spontaneously develops thyroid cancer with metastasis similar to humans has provided new opportunities to study contributors to FTC metastasis. This study evaluates the role of gelsolin, an actin-regulatory protein, in modulating the metastatic potential of FTC. Gelsolin was previously found by cDNA microarray analysis to be down-regulated in TR{beta}PV/PV mice as compared with wild type mice. This study found an age-dependent reduction of gelsolin protein abundance in TR{beta}PV/PV mice as tumorigenesis progressed. Knockdown of gelsolin by siRNA resulted in increased tumor cell motility and increased gelsolin expression by histone deacetylase inhibitor (trichostatin A) led to decreased cell motility. Additional biochemical analyses demonstrated that gelsolin physically interacted with TR{beta}1 or PV in vivo and in vitro. The interaction regions were mapped to the C-terminus of gelsolin and the DNA binding domain of TR. The physical interaction of gelsolin with PV reduced its binding to actin, leading to disarrayed cytoskeletal architectures. These results suggest that PV-induced alteration of the actin/gelsolin cytoskeleton contributes to increased cell motility. Thus, the present study uncovered a novel PV-mediated oncogenic pathway that could contribute to the local tumor progression and metastatic potential of thyroid carcinogenesis.


Key words: Thyroid cancer • mutant thyroid hormone receptor • gelsolin • mouse model




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
G. Brabant
Thyrotropin Suppressive Therapy in Thyroid Carcinoma: What Are the Targets?
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1167 - 1169.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society